Caris Launches Landmark Study to Challenge Fragmented Testing in Myeloid Malignancies

<p>First patients enrolled in prospective, multi-institutional study evaluating whether a single Whole Genome Sequencing workflow can replace conventional cytogenetics, FISH and targeted NGS testing IRVING, Texas, Nov. 11, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading...</p>